Who are Intranasal dexmedetomidine-esketamine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intranasal-dexmedetomidine-esketamine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Intranasal dexmedetomidine-esketamine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intranasal dexmedetomidine-esketamine (Intranasal dexmedetomidine-esketamine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic agonist / NMDA receptor antagonist combination. Area: Anesthesia / Sedation / Acute Pain Management.

marketed Alpha-2 adrenergic agonist / NMDA receptor antagonist combination Alpha-2 adrenergic receptors; NMDA receptor Anesthesia / Sedation / Acute Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Intranasal dexmedetomidine-esketamine (Intranasal dexmedetomidine-esketamine) — Peking University First Hospital. This combination drug acts as an alpha-2 adrenergic agonist (dexmedetomidine) and an NMDA receptor antagonist (esketamine) delivered intranasally to produce rapid sedation and analgesia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intranasal dexmedetomidine-esketamine TARGET	Intranasal dexmedetomidine-esketamine	Peking University First Hospital	marketed	Alpha-2 adrenergic agonist / NMDA receptor antagonist combination	Alpha-2 adrenergic receptors; NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic agonist / NMDA receptor antagonist combination class)

Peking University First Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intranasal dexmedetomidine-esketamine — Competitive Intelligence Brief. https://druglandscape.com/ci/intranasal-dexmedetomidine-esketamine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab